WANT TO RECOVER
2X MORE CELLS?
FreezOpt shown to double cell recovery
compared to conventional methods
FreezOpt™ from HOHCells offers peer-reviewed performance that protects your valuable samples from bench to freezer and back again.
The problem
with current methods
Every day, labs discard thousands of dollars in stem and immune cells
Not because of mistakes but because traditional freezing methods without consistent initiation of ice formation lack consistency and may achieve only ~50% post-thaw viability. Half of every precious sample is lost. This wastes research funding, limits manufacturing scalability, and slows progress toward life-saving therapies.
— There’s a better way.
The HOHCells solution
FreezOpt™
Transformational Cryopreservation Technology
FreezOpt is our proprietary ice initiating system engineered specifically for stress-sensitive, high-value cells. In rigorous, peer-reviewed studies, FreezOpt achieved 96.7% viability compared to just 52.7% with conventional methods—nearly doubling viable cell recovery while maintaining cellular function, morphology, and potency.
— This isn’t incremental improvement. It’s a fundamental shift in how we preserve living cells.
96.7%
Post-thaw
viability1
2X
Cell recovery
vs standard cyro 1
$1,080
Est. savings per vial via improved cell recovery2
- Results observed in studies. Your results may vary.
- Based on analysis of all costs associated with stem cell sample collection, and the cost of approximately 50% post-thaw loss of those cells with standard cryopreservation methods.
Why FreezOpt?
Designed to accelerate
next-generation stem, immune, and other stress-vulnerable cell research
Superior
Cell Recovery
Achieve 90%+ viability with near doubling of viable cells post-thaw. Proven performance across microtissues, organoids, stem cells, primary cells, and engineered cell lines.
Aligned with
Cell Research
Designed to support translational research and upstream process development for cell therapies. Enables consistent, high-quality preservation across diverse cell types.
Peer-Reviewed Performance
Rigorously validated in independent studies. Published results demonstrate robust cell morphology and function comparable to fresh cells.
Backed by leading institutions
Science-Driven.
Commercially Validated.
Founded on breakthrough research from Dr. Xiaoming (Shawn) He and the He Research Group’s Multiscale Biomaterials Engineering (MBE) Laboratory at the University of Maryland. Supported by competitive grant funding. Protected by an issued U.S. patent with additional patents pending.
Ready to double your cell recovery?
Join leading research institutions and biotech companies using FreezOpt to advance cell research development.